NeuImmune, founded in Maryland, is an early-stage biopharmaceutical company dedicated to developing innovative vaccines and biopharmaceuticals. The company's core mission is to address critical medical and public health needs through precision glycoengineering and the delivery of biologics. NeuImmune aims to provide safer and more effective prophylactic and therapeutic treatments, focusing on creating bespoke glycosylation signatures that enhance the efficacy of their products.
NeuImmune's team includes leading experts in biopharmaceuticals and vaccine development, supported by a distinguished Scientific Advisory Board. The company has garnered attention for its cutting-edge approach to glycoengineering, positioning itself as a pioneer in the field. Though still in its early stages, NeuImmune has made significant strides in its pipeline, promising impactful advancements in public health and medical treatments.
